What is Zevra Therapeutics Forward Dividend Yield %?
As of today (2024-06-09), the Forward Annual Dividend Yield of Zevra Therapeutics is 0.00%.
As of today (2024-06-09), the Trailing Annual Dividend Yield of Zevra Therapeutics is 0.00%.
ZVRA's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.68 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Zevra Therapeutics's Forward Dividend Yield %
For the Biotechnology subindustry, Zevra Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Zevra Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Zevra Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Zevra Therapeutics (Zevra Therapeutics) Business Description
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVRA has been successfully added to your